Sulodexide
- Generic Name
- Sulodexide
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 57821-29-1
- Unique Ingredient Identifier
- 75HGV0062C
- Background
Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).
- Indication
Sulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion. Also investigated in the treatment of diabetic kidney disease and diabetic neuropathy. New anti-inflammatory properties have a...
- Associated Conditions
- Venous Leg Ulcer (VLU), Chronic Venous Ulcers
- Associated Therapies
- -
The Efficacy and Safety Study of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2009-10-30
- Lead Sponsor
- Corbridge Group Philippines, Inc.
- Target Recruit Count
- 1508
- Registration Number
- NCT01000545
- Locations
- 🇵🇭
Mary Mediatrix Medical Center, Lipa City, Batangas, Philippines
🇵🇭Rizal Private Clinics, Metro Manila, Rizal, Philippines
🇵🇭Holy Child Hospital, Dumaguete City, Philippines
Sulodexide Treatment in Patients With Dense Deposit Disease
- First Posted Date
- 2007-12-31
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- University of Iowa
- Registration Number
- NCT00583427
- Locations
- 🇺🇸
Richard Smith, MD, Iowa City, Iowa, United States
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00462202
- Locations
- 🇦🇺
Monash Medical Center, Melbourne, Victoria, Australia
Effect of Sulodexide in Overt Diabetic Nephropathy
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 968
- Registration Number
- NCT00130312
- Locations
- 🇺🇸
The Collaborative Study Group, Clinical Coordinating Center for U.S. and Canadian clinics, Rush University Medical Center, Chicago, Illinois, United States
🇳🇱The Collaborative Study Group, Clinical Coordinating Center for European Clinics, University of Groningen, Groningen, Netherlands
🇦🇺The Collaborative Study Group, Clinical Coordinating Center for the Pacific Region, Monash Medical Center, Melbourne, Victoria, Australia
Effect of Sulodexide in Early Diabetic Nephropathy
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 1056
- Registration Number
- NCT00130208
- Locations
- 🇳🇱
The Collaborative Study Group, Clinical Coordinating Center for European Clinics, University of Groningen, Groningen, Netherlands
🇺🇸The Collaborative Study Group, Clinical Coordinating Center for U.S. and Canadian Clinics, Rush University Medical Center, Chicago, Illinois, United States
🇦🇺The Collaborative Study Group, Clinical Coordinating Center for the Pacific Region, Monash Medical Center, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.